Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

• Rodney P. Rocconi,
• Laura Stanbery,
• Min Tang,
• Luciana Madeira da Silva,
• Adam Walter,
• Bradley J. Monk,
• Thomas J. Herzog,
• Robert L. Coleman,
• Luisa Manning,
• Gladice Wallraven,
• Staci Horvath,
• Ernest Bognar,
• Neil Senzer,
• Scott Brun,
• John Nemunaitis

Affiliations

Rodney P. Rocconi

University of Alabama at Birmingham, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology

Laura Stanbery

Gradalis, Inc

Min Tang

Stat-Beyond Consulting

Luciana Madeira da Silva

Mitchell Cancer Institute, Division of Gynecologic Oncology, University of South Alabama

Adam Walter

Gradalis, Inc

Bradley J. Monk

Arizona Oncology, (US Oncology Network), University of Arizona, Creighton University

Thomas J. Herzog

University of Cincinnati Cancer Center

Robert L. Coleman

US Oncology Research

Luisa Manning

Gradalis, Inc

Gladice Wallraven

Gradalis, Inc

Staci Horvath

Gradalis, Inc

Ernest Bognar

Gradalis, Inc

Neil Senzer

Gradalis, Inc

Scott Brun

Gold Mast Consulting, LLC

John Nemunaitis

Gradalis, Inc